NCT06048302View on ClinicalTrials.gov

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

March 12, 2024

Study Completion Date

March 19, 2024

Conditions
Hepatic ImpairmentHealthy
Interventions
DRUG

Obicetrapib

1 single dose of obicetrapib

Trial Locations (2)

55114

Nucleus Network, Saint Paul

78215

The American Research Corporation, San Antonio

Sponsors

Collaborators (1)

Veranex
All Listed Sponsors
collaborator

Veranex

UNKNOWN

lead

NewAmsterdam Pharma

INDUSTRY